data

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…

4 months ago
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingCompass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and…

4 months ago
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 08, 2024 10:00 ET | Source: Medicenna Therapeutics Corp.    MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT…

4 months ago
SEALSQs Secure Digital Identity Ecosystem, Designed to Fortify 5G Networks Against Cyber Threats, Safeguards User Privacy and Upholds Data SovereigntySEALSQs Secure Digital Identity Ecosystem, Designed to Fortify 5G Networks Against Cyber Threats, Safeguards User Privacy and Upholds Data Sovereignty

SEALSQs Secure Digital Identity Ecosystem, Designed to Fortify 5G Networks Against Cyber Threats, Safeguards User Privacy and Upholds Data Sovereignty

November 08, 2024 09:10 ET | Source: SEALSQ Geneva, Switzerland, Nov. 08, 2024 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES)…

4 months ago
Data Storage Corporation Provides Letter to Shareholders Highlighting Recent Achievements within CloudFirst Technologies SubsidiaryData Storage Corporation Provides Letter to Shareholders Highlighting Recent Achievements within CloudFirst Technologies Subsidiary

Data Storage Corporation Provides Letter to Shareholders Highlighting Recent Achievements within CloudFirst Technologies Subsidiary

CloudFirst Continues Strong Financial Performance Along with Expansion into the United Kingdom and Operational Success Following Flagship Solutions Group Integration…

5 months ago
AI adoption accelerates across Asia Pacific, strategic data management remains key: New Digital Realty studyAI adoption accelerates across Asia Pacific, strategic data management remains key: New Digital Realty study

AI adoption accelerates across Asia Pacific, strategic data management remains key: New Digital Realty study

Robust and sustainable infrastructure essential to maximize AI investments SINGAPORE, Nov. 4, 2024 /PRNewswire/ -- Digital Realty (NYSE: DLR), the largest…

5 months ago
AI adoption accelerates across Asia Pacific, strategic data management remains key: New Digital Realty studyAI adoption accelerates across Asia Pacific, strategic data management remains key: New Digital Realty study

AI adoption accelerates across Asia Pacific, strategic data management remains key: New Digital Realty study

Robust and sustainable infrastructure essential to maximize AI investments SINGAPORE, Nov. 4, 2024 /PRNewswire/ -- Digital Realty (NYSE: DLR), the largest…

5 months ago
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer SymposiumOnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

November 01, 2024 17:30 ET | Source: OnKure Therapeutics, Inc. OnKure to host a conference call to review key data…

5 months ago
Show previous Posts